Pan-Coronavirus Vaccines for Humans and Wildlife Being Made in Saskatoon?
Updated: Jan 24
My last article on the mystifying Saskatoon BLT-L project explained how it involves Canada, the US government, the Chinese government, three top US scientists, aborted baby organs and human/mice chimeras. Ever since I learned that hundreds of babies are being sacrificed to make BLT-L mice to test COVID-19 vaccines at the University of Saskatchewan, I've had a growing conviction that something very nefarious is in play, and the evidence now shows that a COVID-19 vaccine purporting to immunize against all coronavirus variants is in development, in addition to evidence pointing to a similar vaccine for wildlife populations.
Update on Dr. Angela Rasmussen
In my previous article, I identified Dr. Angela Rasmussen as a person of great interest. Her sudden move from a prestigious position at Georgetown University to a post at VIDO-InterVac, located in an obscure Canadian university town was baffling to many in the scientific community, but it has since become clear that she is playing a major role in Canada's enormous CoVaRR Network, the Canadian government's multi-million dollar response to emerging COVID variants.
There are thirteen "pillars" in the network, and Angela Rasmussen is team leader for Pillar Two, the focus of which is "Host-Pathogen Interactions", in other words, "exploring interactions between SARS-CoV-2 variants and different host species to understand infection and disease, both in the laboratory and the field."
The Zoonotic Spillover Theory
Angela Rasmussen is a fervent promoter of the zoonotic spillover theory that SARS-CoV2 was transmitted to humans by wild animals. As she states in a January 13, 2021 Nature article on the origins of SARS-CoV2: "the overwhelming conclusion is that this virus, too, found its way into a human host through a series of unhappy accidental encounters with animals."
In a June 4, 2021 Washington Post article, Angela airily dismisses the theory that SARS-CoV2 may have leaked from a lab in the Wuhan Institute of Virology as "quite a coincidence," and suggests the wildlife markets in Wuhan as the more likely cause. She acknowledges that study into a possible lab leak is warranted, but she also calls for a "search for animal hosts that could have transmitted SARS-CoV-2 to humans."
(One may be tempted to wonder if Angela's interest in the zoonotic spillover theory may be related to a need to divert attention away from her colleagues' potential involvement with a Wuhan lab leak, but that is a story for another day.)
Angela Rasmussen's Deep Ties to DARPA and DTRA
Angela has worked on contracts for DARPA and DTRA involving animal host responses to MERS and Ebola. Her CV states that she was Principal Investigator on a cooperative agreement with the Defense Advanced Research Projects Agency (DARPA) to investigate host responses to Ebola virus and MERS-CoV. It also states that she worked on contracts from DTRA, National Biodefense and Countermeasures Center (NBACC) in the Department of Homeland Security (DHS), studying "host transcriptional response to infection with multiple emerging pathogens." While at the Columbia University Center for Infection and Immunity, she and her boss, Dr. W. Ian Lipkin, received a $1,928,869 grant from the Defense Threat Reduction Agency.
In 2019 DARPA awarded up to $9.37 million to an international team of scientists ostensibly to protect US military forces from deadly zoonotic viruses that jump from animals to humans.
The three-and-a-half-year project, part of the Preventing Emerging Pathogenic Threats (PREEMPT) program, is to predict where zoonotic viruses might arise and then prevent them from spilling over into humans . . . The team's role will be "to develop novel vaccine approaches to enable scalable vaccination of remote and hard-to-reach wildlife animal populations that harbor these zoonotic viruses.
Incidentally, the University of Saskatchewan, where VIDO-InterVac is located, has received over $1 million in funding from the Defense Threat Reduction Agency (DTRA) since 2018, as well as funding from the HHS and NIH.
CMV: Wildlife Vaccine Delivery Vehicle
How to immunize wildlife populations? A daunting task by any measure. Wild animals are usually immunized via injection or vaccine-laden bait, but this takes time and is not always feasible. PREEMPT scientists propose making transmissible vaccines for animals by engineering a relatively harmless virus that would function as a vaccine delivery vehicle. A likely candidate is CMV (cytomegalovirus).
This rings a bell since the human fetal lung patches of the BLT-L and LoM mouse models engineered by Ralph Baric in 2019 at the University of North Carolina were infected with CMV. From the Introduction:
"We demonstrate that emerging and clinically relevant human pathogens such as Middle East respiratory syndrome coronavirus, Zika virus, respiratory syncytial virus and cytomegalovirus replicate in vivo in these lung implants."
As explained in a previous article, hundreds of BLT-L mice (humanized with human fetal liver, thymus and lung) are being produced at the University of Saskatchewan in collaboration with VIDO-InterVac. The BLT-L mouse project manager, Kerry Lavender explained in her pod cast interview available here, that a few weeks after surgery the mice are sent across campus to Darryl Falzarano at VIDO-InterVac where he infects the fetal human lung patches with SARS-CoV2.
Darryl Falzarano, Expert in Animal Vaccines
Darryl Falzarano is the inventor of a MERS vaccine for camels. As he explains in his video interview, camels are a reservoir for MERS, so he claims the most efficient way to prevent transmission to humans is to vaccinate the camels rather than the people.
Darryl Falzarano is listed on the CoVarrNet website as a team member of Pillar 2. As explained in my previous articles, Darryl Falzarano completed his post-doctoral training at the NIH Rocky Mountain Labs in Hamilton, MT. Kerry Lavender worked as an NIH researcher for several years at Rocky Mountain Labs developing the BLT mouse model. Angela Rasmussen also did a stint at Rocky Mountain Labs overseeing a BSL4 containment lab.
Rocky Mountain Labs and VIDO-InterVac: Animal Vaccine Specialists
The NIH Rocky Mountain Laboratories in Hamilton, MT, has been heavily involved in the creation of Rocky Mountain Laboratories opened in 1928 to study Rocky Mountain spotted fever and enlarged its program to study zoonotic (passed from animals to humans) diseases. The facility is credited with developing vaccines for Rocky Mountain spotted fever and yellow fever.
VIDO-InterVac in Saskatoon, Canada, an international vaccine research center on the campus of the University of Saskatchewan, also specializes in animal vaccines.
It is worth noting that VIDO's director, Dr. Volker Gerdts announced in August, 2021, that they will be operating their facility to the highest level of containment, a BSL-4. (BSL-4 labs are appropriate for work with pathogens that could be easily airborne-transmitted and cause severe to fatal disease in humans for which there are no available vaccines or treatments.)
Animals Are a Threat
CoVaRR-Net's Executive Director, Marc-André Langlois, in a November 29, 2021 McLeans' report, confessed his deep concern about animal reservoirs of emerging coronavirus variants:
The greatest threat will come from a variant that returns to an animal reservoir—infecting your domestic cat, for example, then mutating in your cat in a certain way that the human system will not allow. And then the virus would be transmitted back to humans in this slightly different form. This is what we consider the No. 1 threat to the current vaccines . . . because such a change could render all of them ineffective.
That is why Langlois' network established Pillar Two of the CoVaRR Network, directed by Angela Rasmussen, who, in the same article, points fearfully to the incidence of COVID- infected zoo tigers:
It’s not lost on me that a lot of the zoo animals that have been infected are big cats. There’s already quite a bit of data suggesting not only that cats can be infected, but that they can transmit it to each other.
With her DARPA and DRTA background explained above, along with Darryl Falzarano's and VIDO's animal vaccine expertise, it appears more than likely that the CoVaRR Network is developing a wide-scale COVID vaccine for wildlife populations. The fact that Kerry Lavender's BLT-L mice were infected with CMV, the vaccine delivery vehicle of choice for a COVID animal vaccine, fortifies the possibility.
The stated goal of Darryl Falzarano and Kerry Lavender's joint project, "Coronaviruses – animal model and vaccine development" is "the development of pan-coronavirus vaccines that could provide protection against multiple strains or cluster of viruses."
It was openly acknowledged in the McLean's article on CoVaRR Network that the current vaccines were not doing the job.
Hopes that vaccines could put a stop to this pandemic as quickly as it began were dashed in Canada when health-care systems in Western provinces became overwhelmed with last summer’s surge of new cases.
A Clearer Picture of the Gruesome BLT-L Mouse Project Emerges
This huge, multi-million dollar endeavor appears to be focused now on developing a master vaccine that will allegedly stop emerging variants, and the scheme appears to include plans to immunize vast numbers of wild life which are seen as a threat to human populations. One wonders if this will lead to the mass culling of animals suspected of harboring coronavirus variants, such as occurred in the Netherlands last year when 17 million minks were euthanized.
Whatever is being planned, it involves the sacrifice of hundreds of aborted babies whose liver, thymus and lungs are required for the engineering of the humanized test mice vital to vaccine development, and that ongoing atrocity is what is driving my interest in Saskatoon.